Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hana creates alternative to antiemetic tablets
The current treatment, an antiemetic drug, comes in tablet form and is just as effective as the oral spray. Hana believes its new medication could be an alternative
The current treatment, an antiemetic drug, comes in tablet form and is just as effective as the oral spray. Hana believes its new medication could be an alternative
Novartis has developed the breakthrough therapy that will allow patients receiving blood transfusions to be administered iron chelation from a drink rather than the current therapy from infusion.
Influenza infects approximately 5-15% of the world’s population in a typical year, resulting in 250,000 to 500,000 deaths, according to the World Health Organization. Additional grants for program
Chrysalin was being developed to accelerate bone healing in the case of wrist fractures. The study was to test the safety and efficacy of the doses of Chrysalin
The findings suggest that managing stress and reducing certain medications prescribed for the elderly could slow down the progression of this devastating disease. In a study with genetically
The FDA’s revised action date for the drug, which is a derivative of the company’s popular Effexor XR, will now be January 22, 2007. The company said that
The DNA technology is being designed to vaccinate against lethal viral outbreaks including avian influenza. The acquisition of this intellectual property enhances the position of Hemispherx Biopharma in
The new studies of this technology will incorporate influenza genes to assess their improved immunity against influenza and other diseases. “While our initial development efforts will focus on
Novartis will begin supplying Lucentis in the middle of September in Switzerland. The decision by the Swiss Agency for Therapeutic Products comes shortly after the FDA approved Lucentis
The companies will co-develop rPlasmin, a derivative of the human blood component plasmin which is used for treating blood clots. Bausch & Lomb believes this may have potential